ClinicalTrials.gg
RecruitingNCT07206355Map HPBUpdated Apr 29, 2026

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

An observational study in Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) and Cholangiocarcinoma, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Nottingham · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 42 studies in Biliary Tract Neoplasms with a site in United Kingdom — 11 open to participants now, 19 under way, 6 of them phase 3. Biliary Tract Neoplasms · United Kingdom.

Started
2026
the only one that year
Observational
4 of 42
1 open now
Primary completion
2028-09
later than 14 of 18 live
Registered
40th of 42
by date

Among the 42 studies in Biliary Tract Neoplasms with a site in United Kingdom, this one is the only one that started in 2026, is one of 4 observational ones, reaches primary completion later than 14 of the 18 other live ones, and was the 40th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

11 of the 42 studies in Biliary Tract Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Biliary Tract Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Hepato-Pancreato-Biliary (HPB) cancers originating in the liver, bile ducts, pancreas, and gall bladder represent a rising global health challenge, with incidence doubling in the UK over the past decade. Cholangiocarcinoma (CCA) and pancreatic cancer are particularly aggressive, often detected late due to non-specific symptoms and difficulties in sampling or imaging. In the UK, CCA affects around 3,000 people annually, with only 13% surviving 3 years, while pancreatic cancer has a 5-year survival of 8.3%. Diagnosis is complicated by the anatomical narrowness of the bile duct and the similarity between malignant and benign strictures. Standard imaging often cannot distinguish between inflammation and cancer, while tissue sampling is challenging, paucicellular, and limited in sensitivity, necessitating repeated biopsies. Yet, accurate characterisation is critical as NICE now recommends targeted therapies (FGFR2, NTRK, MSI-H/dMMR, IDH1 mutations) that require molecular profiling.

Both CCA and PDAC display high heterogeneity, further complicating treatment. Emerging approaches such as Raman spectroscopy can map malignant tissues by detecting vibrational energy shifts, but require further validation due to weak signals. For focal or cystic HPB lesions not well visualised by conventional imaging, novel modalities like ultra-thin endoscopes with scattering/absorption imaging are being developed for improved early diagnosis.

Management of biliary obstruction frequently involves stenting to restore bile flow, essential for palliation and pre-treatment optimization. However, stent failure from tumour ingrowth, displacement, or erosion remains common, and evidence for best stent use is limited. Novel approaches, including drug-eluting coatings and nanoparticle-mediated wireless treatment delivery, are being investigated.

To overcome diagnostic and therapeutic barriers, flexible snake-like robotic systems with navigation, sampling, spectroscopy, and treatment capabilities are being developed. These devices, alongside ultra-thin endoscopes and integrated Raman spectroscopy, aim to characterise strictures, generate 3D imaging in ex-vivo HPB tissue, and permit targeted ablation. Parallel work will explore molecular and fluid-based biomarkers (blood, bile, cyst fluid) to support minimally invasive diagnosis and monitoring.

Through integration of engineering, molecular diagnostics, and device innovation, this transdisciplinary research programme (UKRI and MRC funded) seeks to transform early detection, accurate diagnosis, and novel treatment of HPB cancers, thereby improving outcomes in CCA, pancreatic malignancy, and other clinically similar biliary disorders.

Aim:

To provide a detailed understanding of the characteristics (including clinical and molecular) of liver and pancreatic biliary focal lesions (inflammatory and cancerous) and create a bioresource of liver, pancreas, gallbladder and biliary tract associated tissue and fluids (biopsies, brushings, resected tissues, bile and cyst fluid and blood samples) in order to develop innovative tools for accurate diagnosis and treatment.

Study Configuration: Prospective Longitudinal Cohort study Setting: Secondary care centre, Nottingham University Hospitals NHS Trust. (NUH).

Co-ordinated by the NIHR Nottingham Biomedical Research Centre Description of interventions: This is an observational study involving collecting tissue or body fluids (such as bile or pancreatic cyst fluid) during clinical care in addition to collection of blood samples (for DNA, serum and plasma) and data collection.

Surplus tissue residual to the requirements for standard care will be stored and used. Additional tissue samples and body fluid samples collected for research at time of clinical investigations will not be increasing the risk of the clinical procedure.

Blood samples will be collected from patients at the time of enrolment in the study. These may be collected before and/ or after diagnosis is secured.

Duration of study: Overall duration: 60 months Outcome measures: - To report the proportion of patients where adequate tissue could be retrieved from HPB biopsy to come to definitive diagnosis using standard of care.

  • To report the proportion of patients where adequate tissue could be retrieved from biopsy to perform molecular characterisation of HPB samples, beyond standard cyto/histology, using advanced optical-spatial technologies currently under development.
  • To report the proportion of patients where definitive diagnosis of mucinous cystic neoplasm could be made in patients with pancreatic cyst using standard care
  • To report the proportion of patients where molecular characterisation beyond standard cyto/histology could be made in patients with pancreatic cyst using exploratory new technologies under development through ex-vivo experiments
  • To report the correlation between Raman Spectroscopy and standard cyto/histology for identification of cancer in HPB samples
03

Conditions studied

  • Biliary Tract Cancer (BTC)
  • Biliary Tract Cancer (CCA)
  • Cholangiocarcinoma
  • Cholangiocarcinoma Cancer
  • Cholangio Carcinoma
  • Pancreatic Cancer
  • Pancreatic Cyst

Keywords

  • biliary tract cancer
  • Pancreatic Cancer
  • Pancreatic Cyst
  • Pancreatic lesions
  • Biliary Tract Cancer (BTC)
  • Cholangiocarcinoma
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing investigations for the diagnosis and treatment of a HPB focal lesions Patients undergoing surgical resection (of liver, pancreas, gallbladder or bile duct)

Eligibility criteria

Inclusion Criteria:

  • Aged 16 years and over
  • Ability to provide to participate in the study
  • Patients attending Nottingham University Hospitals NHS Trust (NUH) as part of standard clinical care for either:

    • the diagnosis and treatment of suspected biliary stricture or any focal lesion in the Hepato-Pancreato-Biliary (HPB) tract (clinically / radiologically) including liver or pancreatic lesion or pancreatic cyst
    • surgical resection treatment of liver, pancreas, or gall bladder including Whipple Procedure (pancreaticoduodenectomy surgery), gall bladder resection (cholecystectomy), hepatic resection

Exclusion Criteria: No exclusion criteria

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients undergoing investigations for the diagnosis and treatment of a HPB focal lesions

    (a) (up to 140 cases) Patients undergoing investigations for the diagnosis and treatment of a HPB focal lesions (in the liver, gall bladder, bile duct, biliary tract or pancreas), including stricture and pancreatic cysts. Investigations will be determined and performed as a part of the standard of care. (The type of investigations varies and is decided by the clinician in charge or multidisciplinary team meeting decision.) These will be performed using either endoscopic or radiologic approaches including: * Endoscopic Ultrasound (EUS) with endoscopic fine needle acquisition of tissue (FNA/FNB/cyst wall biopsy) for pancreatic cysts or any pancreatic lesion, Endoscopic retrograde cholangio-pancreatography (ERCP) and/or cholangioscopy (SpyGlass™ device) for liver or biliary strictures. * Percutaneous sampling of liver or biliary strictures using ultrasound or percutaneous transhepatic cholangiography (PTC) and/or SpyGlass Discover™ cholangioscopy.

  • b. Patients undergoing surgical resection

    (up to 20 cases) Patients undergoing surgical resection (of liver, pancreas, gallbladder or bile duct) as standard of care for any underlying condition.

06

What researchers measure

Primary outcomes

  1. To characterise biliary strictures and hepato-pancreato-biliary (HPB) focal lesions

    To characterise biliary strictures and hepato-pancreato-biliary (HPB) focal lesions to diagnose cancers including cholangiocarcinoma (CCA) in a prospective patient cohort, establishing clinical features (manifestations, pathology, cytology, treatment responses and outcomes) and molecular, cellular, structural and physical properties.

    Time frame: 3 years

Secondary outcomes

  1. To create a database and associated bioresource of HPB tissues

    To create a database and associated bioresource of HPB tissues (, including the liver, bile duct, gallbladder and pancreas), with or without any focal lesion, for analysis of diagnostic and treatment technologies under development in the laboratory (super-slender robot, ultra-thin scattering absorption and shape endoscope, and electrical actuation technology).

    Time frame: 3 years

  2. To develop a library of images

    To develop a library of images (Endoscopic, Radiology, Raman Spectroscopy) of biliary strictures and HPB lesions or HPB resected tissue linked to specific cyto/ histology and molecular information.

    Time frame: 3 years

  3. To correlate Raman Spectroscopic images

    To correlate Raman Spectroscopic images with molecular characteristics of the HPB samples.

    Time frame: 3 years

  4. To identify genetic markers and biomarkers for early diagnosis

    To identify genetic markers and biomarkers for early diagnosis and monitoring of HPB lesions.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2028, 32 months after the start.

Of 44 observational studies under Biliary Tract Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 132. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 3, 2025
StartActual
Jan 25, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2030
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07206355
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Jan 25, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Apr 29, 2026

Study contacts

Saikat Mandal, MBBS, MD, MRCEM
Contact
saikat.mandal@nottingham.ac.uk
(+44) 0115 970 9900
Guruprasad P Aithal, MBBS, MD, PhD
principal investigator · University of Nottingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion